Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-23T06:12:58.987Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis

Published online by Cambridge University Press:  17 October 2017

E Sahin ,
D Dizdar ,
M E Dinc  and
A A Cirik
E Sahin
Affiliation:
Department of Otolaryngology, Head and Neck Surgery, Bayındır Hospital Icerenkoy, Istanbul, Turkey
D Dizdar*
Affiliation:
Department of Otorhinolaryngology, Medical Park Bahçelievler Hospital, Faculty of Medicine, Istanbul Kemerburgaz University, Istanbul, Turkey
M E Dinc
Affiliation:
Department of Otorhinolaryngology, Gaziosmanpasa Taksim Education and Research Hospital, Turkish Ministry of Health, Istanbul, Turkey
A A Cirik
Affiliation:
Department of Otolaryngology, Head and Neck Surgery, Umraniye Research and Training Hospital, Istanbul, Turkey
*
Address for correspondence: Dr Denizhan Dizdar, Department of Otorhinolaryngology, Medical Park Bahçelievler Hospital, Faculty of Medicine, Istanbul Kemerburgaz University, Istanbul, Turkey E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Allergic rhinitis is strongly associated with the presence of house dust mites. This study investigated the long-term effects of allergen-specific immunotherapy. Allergen-specific immunotherapy was applied over three years. The study was based on a 10-year follow up of patients with allergic rhinitis.

Methods:

The study was conducted between 2001 and 2015. Skin prick test results and symptom scores were evaluated before (26 patients) and after 3 years (20 patients) of allergen-specific immunotherapy (using data from a previously published study), and 10 years after allergen-specific immunotherapy had ended (20 of 26 patients).

Results:

The symptom scores before allergen-specific immunotherapy were significantly higher than those obtained after 3 years of allergen-specific immunotherapy and 10 years after allergen-specific immunotherapy (p < 0.0175). There were no significant differences between the scores obtained at 3 years and 10 years after allergen-specific immunotherapy (p > 0.0175).

Conclusion:

Subcutaneous immunotherapy is an effective treatment for house dust mite induced allergic rhinitis.

Keywords

AllergyImmunotherapySubcutaneous Immunotherapy
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 131 , Issue 11 , November 2017 , pp. 997 - 1001
Copyright
Copyright © JLO (1984) Limited 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Platts-Mills, TA, Erwin, EA, Heymann, PW, Woodfolk, JA. Pro: the evidence for a causal role of dust mites in asthma. Am J Respir Crit Care Med 2009;180:109–13Google Scholar
2 Sporik, R, Chapman, MD, Platts-Mills, TA. House dust mite exposure as a cause of asthma. Clin Exp Allergy 1992;22:897–906 Google Scholar
3 Eifan, AO, Calderon, MA, Durham, SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther 2013;13:1543–56Google Scholar
4 Masoli, M, Fabian, D, Holt, S, Beasley, R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469–78Google Scholar
5 Reddel, HK, Bateman, ED, Becker, A, Boulet, LP, Cruz, AA, Drazen, JM et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J 2015;46:622–39CrossRefGoogle Scholar
6 Canonica, GW, Bousquet, J, Mullol, J, Scadding, GK, Virchow, JC. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62:17–25 CrossRefGoogle ScholarPubMed
7 Bahceciler, NN, Cobanoglu, N. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma. Immunotherapy 2011;3:747–56CrossRefGoogle ScholarPubMed
8 Pevec, B, Pevec, MR, Markovic, AS, Batista, I. House dust mite subcutaneous immunotherapy does not induce new sensitization to tropomyosin: does it do the opposite? J Investig Allergol Clin Immunol 2014;24:29–34 Google Scholar
9 Sahin, E, Taş, E, Dağtekin Ergür, EN, Cuhali, BD, Gürsel, AO. The results of specific immunotherapy for house dust mites in patients with allergic rhinitis [in Turkish]. Kulak Burun Bogaz Ihtis Derg 2008;18:79–84 Google Scholar
10 Şahin, E. Comparison of 3-year Clınıcal and Laboratory Results for Dermatophagoides Pteronyssinus and Dermatophagoides Farinae Allergen Specific Immunotherapy, Specialization Thesis [in Turkish]. Istanbul: Turkish Ministry of Health, Bakırkoy Education and Research Hospital, 2005Google Scholar
11 Cingi, C, Bayar, Muluk N, Ulusoy, S, Acar, M, Şirin, S, Çobanoğlu, B et al. Efficacy of sublingual immunotherapy for house dust mite allergic rhinitis. Eur Arch Otorhinolaryngol 2015;272:3341–6CrossRefGoogle ScholarPubMed
12 Lachapelle, JM, Maibach, HI. Patch Testing and Prick Testing: A Practical Guide, 2nd edn. Berlin/Heidelberg: Springer Verlag, 2009 Google Scholar
13 Aricigil, M, Muluk, NB, Sakarya, EU, Sakalar, EG, Senturk, M, Reisacher, W et al. New routes of allergen immunotherapy. Am J Rhinol Allergy 2016;30:193–7Google Scholar
14 Kavut, AB, Kalpaklıoğlu, F. Diagnostic tools for allergic rhinitis and asthma. J Med Updates 2012;2:22–30 Google Scholar
15 Yaz, A, Cingi, C, Gürbüz, MK, Bal, C. The long-term results of the impact of rhinophototherapy on quality of life in cases with allergic rhinitis. J Med Updates 2012;2:63–9Google Scholar
16 Ying, S, Barata, LT, Meng, Q, Grant, JA, Barkans, J, Durham, SR et al. High-affinity immunoglobulin E receptor (Fc epsilon RI)-bearing eosinophils, mast cells, macrophages and Langerhans' cells in allergen-induced late-phase cutaneous reactions in atopic subjects. Immunology 1998;93:281–8Google Scholar
17 Gaga, M, Frew, AJ, Varney, VA, Kay, AB. Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase skin reactions and classical delayed-type hypersensitivity. J Immunol 1991;147:816–22Google Scholar
18 Garcia, BE, Sanz, ML, Gato, JJ, Fernandez, J, Oehling, A. IgG4 blocking effect on the release of antigen-specific histamine. J Investig Allergol Clin Immunol 1993;3:26–33 Google Scholar
19 Iliopoulos, O, Baroody, FM, Naclerio, RM, Bochner, BS, Kagey-Sobotka, A, Lichtenstein, LM. Histamine-containing cells obtained from the nose hours after antigen challenge have functional and phenotypic characteristics of basophils. J Immunol 1992;148:2223–8CrossRefGoogle ScholarPubMed
20 Sampson, AP. The role of eosinophils and neutrophils in inflammation. Clin Exp Allergy 2000;1:22–7Google Scholar
21 Creticos, PS, Esch, RE, Couroux, P, Gentile, D, D'Angelo, P, Whitlow, B et al. Randomized, double-blind, placebo controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol 2014;133:751–8Google Scholar
22 Pevec, B, Radulovic, Pevec M, Stipic, Markovic A, Batista, I, Rijavec, M, Silar, M et al. House dust mite specific immunotherapy alters the basal expression of T regulatory and FcεRI pathway genes. Int Arch Allergy Immunol 2012;159:287–96Google Scholar
23 Jacobsen, L, Niggemann, B, Dreborg, S, Ferdousi, HA, Halken, S, Høst, A et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007;62:943–8Google Scholar
24 Bousquet, J, Lockey, R, Malling, HJ, Alvarez-Cuesta, E, Canonica, GW, Chapman, MD et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:401–5Google Scholar
25 Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007;120(3 suppl):S25–85 Google Scholar
26 Li, JT, Bernstein, DI, Calderon, MA, Casale, TB, Cox, L, Passalacqua, G et al. Sublingual grass and ragweed immunotherapy: clinical considerations--a PRACTALL consensus report. J Allergy Clin Immunol 2016;137:369–76CrossRefGoogle ScholarPubMed